Related Experiment Videos
Thrombospondins and tumor angiogenesis
F de Fraipont1, A C Nicholson, J J Feige
1INSERM EMI 0105, Dept of Molecular and Structural Biology, Commissariat à l'Energie Atomique, Grenoble, France.
Abstract:
The thrombospondins (TSPs) are a family of five secreted proteins that are widely distributed in the extracellular matrix of numerous tissues. TSPs are multimodular and each domain specifies a distinct biological function through interaction with a specific receptor. TSP1 and TSP2 have anti-angiogenic activity, which, at least for TSP1, involves interaction with the microvascular endothelial cell receptor CD36. Expression of TSP1 and TSP2 is modulated by hypoxia and by oncogenes. In several tumors (thyroid, colon, bladder carcinomas), TSP1 expression is inversely correlated with tumor grade and survival rate, whereas in others (e.g. breast carcinomas), it is correlated with the stromal response and is of little prognostic value. Recent studies suggest that TSPs or TSP-derived peptides retaining biological activity could be developed into promising new therapeutic strategies for the anti-angiogenic treatment of solid tumors.
Insights
Thrombospondins (TSPs) are proteins with anti-angiogenic properties. TSPs and their derived peptides show potential as novel therapeutic strategies for treating solid tumors by inhibiting blood vessel formation.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Thrombospondins (TSPs) are secreted proteins found in the extracellular matrix.
- TSPs are multimodular, with domains mediating specific biological functions via receptor interactions.
- TSP1 and TSP2 exhibit anti-angiogenic activity, partly through CD36 receptor binding.
Purpose of the Study:
- To explore the role of TSPs in tumor biology.
- To investigate the therapeutic potential of TSPs and TSP-derived peptides for anti-angiogenic cancer treatment.
Main Methods:
- Analysis of TSP expression patterns in various tumor types.
- Investigation of TSP-receptor interactions, specifically TSP1 and CD36.
- Review of studies on TSP expression modulation by hypoxia and oncogenes.
Main Results:
- TSP1 and TSP2 expression is influenced by hypoxia and oncogenes.
- TSP1 expression shows varied prognostic value across different cancers (e.g., inverse correlation in thyroid, colon, bladder; limited value in breast).
- Recent research highlights TSPs and TSP-derived peptides as potential anti-angiogenic therapeutics.
Conclusions:
- TSPs play a complex role in cancer, with varying prognostic significance.
- The anti-angiogenic properties of TSPs, particularly TSP1, offer a promising avenue for developing new cancer therapies.